Chiara Cosentino

Dr. Chiara Cosentino

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
SFSimone Finocchiaro
Simone Finocchiaro
MMMaria Sara Mauro
Maria Sara Mauro
CBCostanza Bordonaro
Costanza Bordonaro
KBKamil Bujak
Kamil Bujak
CCChiara Cosentino
Chiara Cosentino
DCDavide Capodanno
Davide Capodanno
Recent European and American dyslipidaemia guideline updates mark a relevant shift in preventive cardiology. The 2025 ESC/EAS focused update and the 2026 ACC/AHA guideline share the same biological premise: low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B (ApoB)–containing lipoproteins are causal drivers of atherosclerotic cardiovascular disease, and cardiovascular benefit depends on earlier, deeper, and sustained reduction of atherogenic burden. Their main differences lie in how prevention is organized in clinical practice. The European framework places greater emphasis on the explicit linkage between risk categories, predefined LDL-C goals, and treatment escalation. The American framework gives greater operational weight to lifetime risk, coronary artery calcium, non–high-density lipoprotein cholesterol, ApoB, lipoprotein(a), treatment burden, and shared decision-making more directly into treatment selection. These differences influence patient classification, treatment intensity, and incorporation of non-statin therapies, particularly in borderline-risk primary prevention, subclinical atherosclerosis, and patients requiring combination therapy beyond statins. At the same time, both documents converge on key principles: reduced tolerance for prolonged exposure to atherogenic lipoproteins, broader use of combination lipid-lowering therapy, earlier intensification after acute coronary syndromes and in very high-risk settings, and selective use of biomarkers and imaging to refine prevention. Together, they offer complementary models of contemporary lipid management.

29 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCChiara Cosentino
Chiara Cosentino
LCLuigi Cutore
Luigi Cutore
CRCarmelo Raffo
Carmelo Raffo
CLClaudio Laudani
Claudio Laudani
CCCarmelo Cusmano
Carmelo Cusmano
AGAntonio Greco
Antonio Greco
Historically, beta-blockers have long represented a cornerstone of secondary prevention after acute myocardial infarction (AMI). However, the transition to the modern era of early reperfusion and potent pharmacotherapy has questioned their universal efficacy, particularly in patients without post-AMI left ventricular dysfunction. This review critically analyzes current evidence on the role, timing, and optimal duration of beta-blocker therapy after AMI, with a focus on the impact of left ventricular ejection fraction (LVEF). Relevant literature was identified through searches of PubMed and Web of Science, with particular emphasis on randomized trials and meta-analyses investigating beta-blocker efficacy and safety post-AMI. The search strategy focused on the interaction between LVEF categories and clinical outcomes. Data from historical cohorts and modern trials were synthesized to evaluate the optimal timing and duration of therapy according to the LVEF phenotype. While the survival benefit of beta-blockers remains undisputed for patients with LVEF < 40%, contemporary evidence demonstrates a lack of prognostic advantage for routine beta-blockade in patients with preserved LVEF (i.e., ≥50%). Crucially, recent meta-analyses reveal that patients with LVEF (40–49%) may derive significant benefit from long-term therapy with beta-blockers. Regarding duration, evidence on deprescription remains conflicting. Although earlier data highlighted risks of hemodynamic rebound upon withdrawal, recent trials demonstrate that discontinuing beta-blocker therapy in the chronic phase of AMI may be a safe strategy. Long-term beta-blocker therapy after AMI is supported by robust evidence in patients with LVEF < 40%, whereas emerging but less definitive evidence suggests a potential benefit in those with LVEF 40–49%. Conversely, contemporary randomized trials do not support routine beta-blockade for patients with preserved LVEF (≥50%) in the absence of other clinical indications. As such, further studies are needed to refine patient selection and inform future guideline recommendations across the whole LVEF spectrum.